VolitionRX (NYSE: VNRX) is a clinical-stage life sciences company that focuses on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The company is involved in the development of 28 epigenetic NuQ blood assays based on its Nucleosomics biomarker discovery platform. It develops two blood assays in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides; and three blood tests in the NuQ-V family to detect cancer by detecting nucleosomes containing specific histone variants. VolitionRX also develops 17 blood assays in the NuQ-M family to detect cancer by detecting nucleosomes containing modified histones that are proteins for packaging and ordering DNA into nucleosomes; 5 blood assays in the NuQ-A family to detect cancer by detecting nucleosome-protein adducts; and a NuQ-T assay to detect cancer by detecting total blood nucleosome levels. For more information, visit the company’s website at www.volitionrx.com.
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
